Met-Enkephalin

Most Common Uses

Met-enkephalin is integral to several physiological processes due to its role as an endogenous neurotransmitter and neuromodulator. It binds to opioid receptors in the brain and spinal cord to modulate pain perception, supporting the body’s natural mechanisms for pain relief, particularly during stress or injury, by reducing discomfort. The peptide also contributes to managing the body’s response to stress, as it is released in the central nervous system to regulate emotional and physiological reactions, fostering a sense of calm in challenging situations. Additionally, Met-enkephalin acts as a signaling molecule within the nervous system, facilitating neuron communication and influencing mood, behavior, and other neurological functions through its interaction with mu-opioid receptors.

Researchers study it to explore its potential in understanding conditions such as depression, anxiety, and addiction, given its impact on the brain’s reward system, making it a focal point for developing treatments for these disorders. Met-enkephalin is investigated for its role in immune function, as it is present in immune cells and tissues and may help modulate immune responses, particularly in inflammatory conditions. Although not used directly as a medication, it inspires the development of synthetic analogs for pain relief, aiming to replicate its pain-relieving effects while minimizing side effects compared to traditional opioids. Met-enkephalin’s wide-ranging roles underscore its significance in both physiological processes and medical research.

Mechanism of Action

Met-enkephalin exerts its effects primarily through interactions with opioid receptors in the central and peripheral nervous systems. Composed of the amino acid sequence Tyr-Gly-Gly-Phe-Met, this pentapeptide binds predominantly to mu-opioid receptors, with some affinity for delta-opioid receptors. Upon binding, it activates these G-protein-coupled receptors, initiating a cascade of intracellular signaling events. This activation inhibits adenylate cyclase, reducing cyclic AMP levels, which modulates neuronal excitability. Additionally, Met-enkephalin promotes the opening of potassium channels and inhibits calcium channels, leading to hyperpolarization of neurons and decreased neurotransmitter release.

These actions result in reduced pain perception, as the peptide dampens the transmission of pain signals in the spinal cord and brain. Beyond pain modulation, Met-enkephalin influences mood, stress responses, and reward pathways, contributing to its role in emotional regulation. Its effects are short-lived due to rapid degradation by enzymes such as enkephalinases, which cleave the peptide in extracellular spaces. This mechanism underpins Met-enkephalin’s role in natural pain relief, stress adaptation, and neurological signaling, making it a significant focus in neuroscientific research.

Structure and Pharmacology

Met-enkephalin consists of a five-amino-acid sequence: tyrosine-glycine-glycine-phenylalanine-methionine (H-Tyr-Gly-Gly-Phe-Met-OH). This compact structure, with a molecular weight of approximately 573.7 g/mol and a molecular formula of C27H35N5O7S, enables its role as a neurotransmitter and neuromodulator. The peptide’s tyrosine residue at the N-terminus facilitates binding to opioid receptors, while the methionine at the C-terminus distinguishes it from its counterpart, Leu-enkephalin. Its small size and specific amino acid arrangement allow precise interactions with receptor sites in the nervous system.

Pharmacologically, Met-enkephalin exerts its effects primarily through binding to mu-opioid receptors, with moderate affinity for delta-opioid receptors, in the brain, spinal cord, and peripheral tissues. This binding activates G-protein-coupled signaling pathways, inhibiting adenylate cyclase to reduce cyclic AMP levels, which modulates neuronal activity. The peptide also promotes potassium channel opening and inhibits calcium channels, hyperpolarizing neurons and reducing neurotransmitter release. These actions contribute to analgesia, mood regulation, and stress response modulation. Met-enkephalin’s short half-life results from rapid degradation by peptidases, such as enkephalinases, limiting its duration of action. Its pharmacological profile inspires research into synthetic analogs for pain management and neurological disorders, aiming to extend its therapeutic effects while minimizing side effects.

Dosages

Met-enkephalin is not administered as a pharmaceutical drug due to its rapid degradation in the body and short half-life. As a naturally occurring peptide produced in the brain and other tissues, it does not have standardized therapeutic dosages like synthetic medications. Instead, its physiological effects arise from endogenous release in response to stimuli such as pain or stress, with concentrations varying based on individual biological factors. Research exploring Met-enkephalin or its synthetic analogs for potential therapeutic use, such as pain management or neurological disorders, typically involves experimental settings rather than clinical dosing regimens.

In these studies, analogs designed to resist enzymatic breakdown may be administered in controlled amounts, often in microgram or milligram ranges, depending on the delivery method, such as intravenous or intrathecal injection. However, specific dosage guidelines for Met-enkephalin itself remain undefined in clinical practice, as its use is primarily investigational. Ongoing research aims to develop stable derivatives that mimic its effects, potentially leading to defined dosages for future therapeutic applications.

Warnings and Cautions

Met-enkephalin is not used as a clinical medication, so direct warnings and cautions apply primarily to its research and potential therapeutic analogs. As a naturally occurring peptide, it is produced in the body to modulate pain and stress responses, but its rapid degradation by enzymes like enkephalinases limits its practical use in medical settings. Researchers handling Met-enkephalin or its synthetic analogs in experimental studies should exercise caution due to its opioid-like effects, which may influence pain perception, mood, and neurological function through mu-opioid and delta-opioid receptor activation.

Excessive or uncontrolled administration of analogs in research could lead to unintended side effects, such as sedation, respiratory depression, or altered emotional states, similar to other opioids. People with a history of opioid sensitivity or substance use disorders may require special consideration in studies involving Met-enkephalin derivatives to avoid potential adverse reactions. Laboratory handling of this peptide demands strict adherence to safety protocols, as improper use or exposure could affect neurological or immune responses. Pregnant or breastfeeding women should avoid exposure to synthetic analogs in research settings, as their effects on fetal or infant development remain understudied. Any experimental use of Met-enkephalin-based compounds should occur under rigorous medical supervision to ensure safety and monitor for unexpected physiological impacts.

Research & Trials

Endogenous Opiates: 1996

The 1997 review found that the body’s natural opioid system does much more than just control pain. Research from 1996 showed that these natural chemicals affect many different areas, including stress, addiction, eating and drinking habits, digestion, mood, memory, heart function, breathing, seizures, movement, reproduction, the immune system, and even social behavior. Their effects weren’t always the same, they depended on things like the type of stress, the dose, which receptors were involved, genetics, and the situation. For example, drugs like morphine usually increased eating and movement, reduced seizures, and had mixed effects on the immune system, while opioid blockers often did the opposite. One natural opioid, Met-enkephalin, was linked to slowed breathing, showing how powerful these chemicals can be in the body. The review also noted that exposure to opioids before birth could change sexual development and social behavior later in life. Overall, the review highlighted that the body’s opioid system is deeply involved in many aspects of health and behavior, but its effects are complicated and can vary depending on the circumstances. [1]

Hepatoprotective Effects of Met-enkephalin in Mice

The study found that Met-enkephalin strongly protects the liver from damage caused by acetaminophen in mice. The best results came from a dose of 7.5 mg/kg, which greatly lowered levels of liver enzymes (ALT and AST) in the blood and reduced liver cell damage compared to untreated animals. The protective effect followed a U-shaped pattern, meaning that medium doses worked best, while very small or very large doses were less helpful. The researchers showed that these benefits worked specifically through the δ and ζ opioid receptors, because blocking these receptors with naltrexone, or blocking Met-enkephalin itself with a special peptide, completely removed its protective effects. Importantly, safety testing showed that Met-enkephalin was not harmful to genetic material. Overall, the study showed that Met-enkephalin protects the liver in a receptor-specific and dose-dependent way, making it a promising option for preventing liver damage caused by drugs. [2]